It has been shown that there is a paradox between Adiponectin and mortality in patients with cardiovascular disease, and that Adiponectin is positively associated with mortality in a variety of clinical conditions, including diabetes mellitus, which is related to confounding between lipocalin resistance and natriuretic peptides, and may be due to a combination of genetic, environmental, and dietary differences in different racial and regional populations. The gene discussed is ADIPOQ; the disease is cardiovascular disorder.